Correlation between Serum Cytokeratin 19 Fragment and the Clinicopathological Features and Prognosis of Thymic Epithelial Tumors.
10.3779/j.issn.1009-3419.2018.07.03
- Author:
Xuefei ZHANG
1
;
Chunyu JI
1
;
Zhitao GU
1
;
Wentao FANG
1
Author Information
1. Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China.
- Publication Type:Journal Article
- Keywords:
Cyfra 21-1;
Histotype;
Prognosis;
Thymic epithelial tumors;
Tumor stage
- MeSH:
Biomarkers, Tumor;
blood;
Female;
Follow-Up Studies;
Humans;
Keratin-19;
blood;
chemistry;
Male;
Middle Aged;
Neoplasms, Glandular and Epithelial;
blood;
diagnosis;
pathology;
Peptide Fragments;
blood;
Prognosis;
ROC Curve;
Retrospective Studies;
Thymus Neoplasms;
blood;
diagnosis;
pathology
- From:
Chinese Journal of Lung Cancer
2018;21(7):519-525
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:So far there's no tumor maker applied in diagnosis and treatment of thymic epithelial tumors. This study is to assess the correlation between serum cytokine 19 fragment (Cyfra 21-1) and clinicopathological features and prognosis of thymic epithelial tumors (TETs).
METHODS:The clinical data of 159 patients with TETs in Shanghai Chest Hospital was retrospectively analysed. Patients were divided into groups according to different tumor stages and histotypes. Serum Cyfra 21-1 was thus compared. In addition, the possible relationship between perioperative serum Cyfra 21-1 level and the recurrent status was carrid out.
RESULTS:Preoperative Cyfra 21-1 serum concentrations in patiants with advanced stage (T4) and thymic carcinomas were significantly higher than that in others (P<0.001, P<0.001, respectively). When the preoperative serum level exceeds the out-off of 1.66 ng/mL, it possibly indicates the recurrence during follow up. Furthermore, the sensitivity, specificity, and positive as well as negative predictive value (PPV and NPV) of postoperative Cyfra 21-1 to predict tumor recurrence were evaluated. At a cut-off of Cyfra 21-1 of 2.66 ng/mL, the sensitivity was 0.7, the specificity was 0.925, the PPV was 0.5 and the NPV was 0.966.
CONCLUSIONS:The elevated level of preoperative serum Cyfra 21-1 indicates an advanced stage of tumor or a more malignant histotype (thymic carcinoma). It also probably suggests a higher risk of tumor recurrence. During the oncological follow up, in addition to regular imaging examinations, the blood test of serum Cyfra 21-1 is also suggested to improve the diagnosis of tumor recurrence in order to improve the prognosis.
